Upgrade to SI Premium - Free Trial

Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

June 12, 2026 8:25 AM
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $427.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "With ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments